Tscan Therapeutics Stock Retained Earnings
| TCRX Stock | USD 7.32 0.03 0.41% |
Tscan Therapeutics fundamentals help investors to digest information that contributes to Tscan Therapeutics' financial success or failures. It also enables traders to predict the movement of Tscan Stock. The fundamental analysis module provides a way to measure Tscan Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tscan Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | -247.6 M | -235.2 M | |
| Retained Earnings Total Equity | -142.5 M | -149.7 M |
Tscan | Retained Earnings |
Tscan Therapeutics Company Retained Earnings Analysis
Tscan Therapeutics' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Tscan Therapeutics Retained Earnings | (247.6 M) |
Most of Tscan Therapeutics' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tscan Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tscan Retained Earnings Driver Correlations
Understanding the fundamental principles of building solid financial models for Tscan Therapeutics is extremely important. It helps to project a fair market value of Tscan Stock properly, considering its historical fundamentals such as Retained Earnings. Since Tscan Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tscan Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tscan Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Tscan Therapeutics has a Retained Earnings of (247.6 Million). This is 126.58% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 102.65% higher than that of the company.
Tscan Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tscan Therapeutics' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tscan Therapeutics could also be used in its relative valuation, which is a method of valuing Tscan Therapeutics by comparing valuation metrics of similar companies.Tscan Therapeutics is currently under evaluation in retained earnings category among related companies.
Tscan Fundamentals
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (2.96) % | ||||
| Current Valuation | 250.89 M | ||||
| Shares Outstanding | 48.59 M | ||||
| Shares Owned By Insiders | 0.91 % | ||||
| Shares Owned By Institutions | 78.79 % | ||||
| Number Of Shares Shorted | 419.69 K | ||||
| Price To Earning | 23.45 X | ||||
| Price To Book | 2.48 X | ||||
| Price To Sales | 17.64 X | ||||
| Revenue | 21.05 M | ||||
| Gross Profit | (46.28 M) | ||||
| EBITDA | (88.1 M) | ||||
| Net Income | (89.22 M) | ||||
| Cash And Equivalents | 125.6 M | ||||
| Cash Per Share | 5.22 X | ||||
| Total Debt | 92.43 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 3.15 X | ||||
| Cash Flow From Operations | (61.36 M) | ||||
| Short Ratio | 2.00 X | ||||
| Earnings Per Share | (1.36) X | ||||
| Target Price | 11.6 | ||||
| Number Of Employees | 154 | ||||
| Beta | 0.9 | ||||
| Market Capitalization | 386.96 M | ||||
| Total Asset | 272.15 M | ||||
| Retained Earnings | (247.6 M) | ||||
| Working Capital | 164.42 M | ||||
| Net Asset | 272.15 M |
About Tscan Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tscan Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tscan Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tscan Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Tscan Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tscan Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tscan Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tscan Therapeutics Stock:Check out Tscan Therapeutics Piotroski F Score and Tscan Therapeutics Altman Z Score analysis. For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Tscan Stock analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Tscan Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tscan Therapeutics. If investors know Tscan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tscan Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.36) | Revenue Per Share 0.321 | Quarterly Revenue Growth 1.33 | Return On Assets (0.25) | Return On Equity (0.71) |
The market value of Tscan Therapeutics is measured differently than its book value, which is the value of Tscan that is recorded on the company's balance sheet. Investors also form their own opinion of Tscan Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tscan Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tscan Therapeutics' market value can be influenced by many factors that don't directly affect Tscan Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tscan Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tscan Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tscan Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.